Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2011

01.01.2011 | Original Paper

Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?

verfasst von: Hirofumi Asakura, Takayuki Hashimoto, Hideyuki Harada, Masashi Mizumoto, Kazuhisa Furutani, Noriaki Hasuike, Masaki Matsuoka, Hiroyuki Ono, Narikazu Boku, Tetsuo Nishimura

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the effectiveness of short-course radiotherapy (RT) with 30 Gy in 10 fractions for bleeding from advanced gastric cancer.

Methods

We reviewed the data for all patients with gastric cancer requiring blood transfusions due to gastric bleeding who were treated with RT at the Shizuoka Cancer Center Hospital between September 2002 and March 2007. Patients with curative-intent chemoradiotherapy or previous irradiation were excluded. RT was planned to deliver a total of 30 Gy at 3 Gy per fraction. We defined RT as effective if the patients did not require blood transfusions for 1 or more months after RT.

Results

Twenty-two out of 30 patients (73%) responded to RT, and rebleeding occurred in 11 (50%) of 22 patients responding to RT. The median actuarial time to rebleeding was 3.3 months. Twelve patients received concurrent chemoradiotherapy and had a significantly lower rebleeding rate than patients undergoing RT alone (P = 0.001). Among patients receiving CRT, 1 with grade 3 non-hematological toxicity and 5 with grade 3–4 hematological toxicity were observed. No Grade 3 or higher adverse events were observed in patients treated with RT alone.

Conclusions

RT with 30 Gy in 10 fractions is an adequate treatment for bleeding from advanced gastric cancer, especially in patients with poor prognosis.
Literatur
Zurück zum Zitat Foukakis T, Lundell L, Gubanski M, Lind PA (2007) Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 46:277–285CrossRefPubMed Foukakis T, Lundell L, Gubanski M, Lind PA (2007) Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 46:277–285CrossRefPubMed
Zurück zum Zitat Hashimoto K, Mayahara H, Takashima A, Nakajima TE, Kato K, Hamaguchi T, Ito Y, Yamada Y, Kagami Y, Itami J, Shimada Y (2009) Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol 135:1117–1123CrossRefPubMed Hashimoto K, Mayahara H, Takashima A, Nakajima TE, Kato K, Hamaguchi T, Ito Y, Yamada Y, Kagami Y, Itami J, Shimada Y (2009) Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol 135:1117–1123CrossRefPubMed
Zurück zum Zitat Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S (2008) Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 47:421–427CrossRefPubMed Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S (2008) Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 47:421–427CrossRefPubMed
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730CrossRefPubMed
Zurück zum Zitat Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9:561–570CrossRefPubMed Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9:561–570CrossRefPubMed
Zurück zum Zitat Rivera F, Vega-Villegas ME, López-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315–324CrossRefPubMed Rivera F, Vega-Villegas ME, López-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315–324CrossRefPubMed
Zurück zum Zitat Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M (2007) The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 67:385–388CrossRefPubMed Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M (2007) The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 67:385–388CrossRefPubMed
Zurück zum Zitat Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909CrossRefPubMed Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909CrossRefPubMed
Zurück zum Zitat Wöhrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585–1595CrossRefPubMed Wöhrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585–1595CrossRefPubMed
Zurück zum Zitat Xiong HQ, Gunderson LL, Yao J, Ajani JA (2003) Chemoradiation for resectable gastric cancer. Lancet Oncol 4:498–505CrossRefPubMed Xiong HQ, Gunderson LL, Yao J, Ajani JA (2003) Chemoradiation for resectable gastric cancer. Lancet Oncol 4:498–505CrossRefPubMed
Metadaten
Titel
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?
verfasst von
Hirofumi Asakura
Takayuki Hashimoto
Hideyuki Harada
Masashi Mizumoto
Kazuhisa Furutani
Noriaki Hasuike
Masaki Matsuoka
Hiroyuki Ono
Narikazu Boku
Tetsuo Nishimura
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0866-z

Weitere Artikel der Ausgabe 1/2011

Journal of Cancer Research and Clinical Oncology 1/2011 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.